Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much weight loss comes with risks.

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved ...

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

A onetime bull now feels the stock is only a hold. Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the ...

Drugmakers are moving to sell their medicines directly to patients, abandoning the middlemen they have long relied on.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...